A new sub study shows that enhanced terminal room disinfection with Tru-D SmartUVC can lead to a decrease in the incidence of targeted multidrug-resistant organisms such as C. diff and VRE for all patients, hospital-wide when used with 93% compliance with standard disinfection protocols. (Individual hospital results may vary.) The study was recently published in The Lancet Infectious Diseases and discusses the prescribed secondary analysis of the BETR-D randomized clinical trial.
Leading researchers in infection prevention and control wanted to conduct a randomized clinical trial that would determine the efficacy, effectiveness and feasibility of enhanced terminal room disinfection to prevent hospital-acquired infections.
LEARN MORE